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Abstract
A negative regulator of the nuclear factor (NF)-kB pathway, A20 (TNFAIP3), is inactivated in several types of lymphomas;
particularly in diffuse large B-cell lymphoma (DLBCL), classical Hodgkin’s lymphoma, and extranodal marginal zone
lymphoma of the mucosa-associated lymphoid tissue. These findings suggest that the NF-kB activation is related to A20
inactivation. Recently, A20 inactivation has also been observed in Epstein-Barr virus (EBV)-related lymphomas; however, this
occurrence has not been well investigated. Moreover, NF-kB is a key molecule in activated B-cell-like (ABC)-type DLBCL; EBV-
associated DLBCL is of the ABC type. Therefore, we focused on A20 deletions in EBV-associated lymphoproliferative
disorders/lymphomas. Using fluorescent in situ hybridization analysis, A20 deletions were identified in 4 of 13 samples from
patients with pyothorax-associated lymphoma (PAL) (31%), 3 of 20 samples from nasal-type NK/T cell lymphomas (NKTLs)
(15%), 1 of 8 samples of EBV-positive DLBCL of the elderly (DLBCL-e) (13%), but not in any of the 11 samples from individuals
with methotrexate-related lymphoproliferative disorder (MTX-LPD) (0%). Among the samples with A20 deletions, EBV latent
membrane protein 1 (LMP-1) expression was detected in all 4 of the PAL samples with A20 deletions and in the DLBCL-e
sample with an A20 deletion, but not in any of the 3 NKTL samples. This finding indicated that A20 deletions were not
directly related to the EBV latency pattern of lymphomas, although such deletions might be related to the diagnostic
category. Immunohistologically, the A20 protein was absent in 2 (15%) of the13 PAL samples, 1 (9%) of 11 MTX-LPD
samples, and in none of the 20 NKTL (0%) or 8 DLBCL-e samples. In conclusion, A20 deletion and/or dysfunctional
expression are frequently associated with PALs, and A20 abnormalities may be related to the pathogenesis of PAL.
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Introduction
Nuclear factor (NF)-kB is an important immunological
transcription factor affecting cancer development and progression
as well as mediating inflammation and autoimmune disease. In
malignant lymphomas, the normal NF-kB pathway is dysregulated
by many genes and molecular abnormalities, including oncogenic
mutations of MALT1 and CARD11 [1,2]. Recently, the inactiva-
tion of A20 has been found to play a significant role in the
pathogenesis of subsets of several lymphomas [3–15].
A20, which is also known as tumor necrosis factor alpha-
induced protein 3 (TNFAIP3), negatively regulates the NF-kB
activation pathway. A20 is frequently inactivated by deletion,
mutation, and/or promoter methylation in several types of
lymphomas, such as extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue (MALT lymphoma) [3–8],
diffuse large B-cell lymphoma (DLBCL) [3,4,9,10], Hodgkin’s
lymphoma [3,11,12], mediastinal large B-cell lymphoma [11],
nodal and splenic marginal zone lymphomas [5,13], follicular
lymphoma [3,4], mantle cell lymphoma [3,4], Burkitt’s lymphoma
[4], and AIDS-related lymphoma [14]. Deletion of A20 has also
been reported in NK/T-cell malignancies: NK-cell lymphoma [4];
adult T-cell leukemia [4]; peripheral T-cell lymphoma, not
otherwise specified [4]; and Se´zary syndrome [15].
In classical Hodgkin’s lymphoma (CHL), A20 alterations are
most commonly observed in patients with nodular sclerosis [3,11].
Schmitz et al. showed that most cases with A20 alterations were
Epstein-Barr virus (EBV)-negative [11]; however, A20 alterations
have been detected in both EBV-negative and EBV-positive
patients [11,12]. Giulino et al. reported A20 alterations in 6 of 33
patients with AIDS-related lymphoma [14], and that most EBV-
positive, AIDS-related lymphoma patients with A20 alterations did
not exhibit latent membrane protein (LMP)-1 expression [14]. As
an activation factor of NF-kB, LMP-1 plays an important role in
the lymphomagenesis of several types of lymphomas. Giulino et al.
suggested that the loss of A20 may be an alternative mechanism of
NF-kB activation in LMP-1-negative, AIDS-related lymphomas
[14].
According to previous reports, the constitutive activation of NF-
kB seems to be related to the deletion of A20 in DLBCL, MALT
lymphoma, and CHL [3–8,11]. To the best of our knowledge, the
association between A20 deletions and EBV-associated lympho-
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e56741
proliferative disorders/lymphomas has not been well studied. We
hypothesized that an association exists, and focused on pyothorax-
associated lymphoma (PAL), nasal-type NK/T-cell lymphoma
(NKTL), EBV-positive DLBCL of the elderly (DLBCL-e), and B-
cell type methotrexate (MTX)-related lymphoproliferative disor-
der (MTX-LPD). We also investigated the association between
A20 deletions and LMP-1 expression.
Materials and Methods
Patient samples
Formalin-fixed, paraffin-embedded samples were obtained from
patients with PAL (16), NKTL (33), DLBCL-e (9), and B-cell type
MTX-LPD (13) at Okayama University Graduate School of
Medicine, Nagoya University Graduate School of Medicine, and
Kurume University School of Medicine, Japan. Diagnoses were
made using the criteria from the World Health Organization [16].
The inclusion criteria required that each sample consist of more
than 80% of the cells being tumor cells and almost all of the tumor
cells were positive for EBV-encoded RNA1 (EBER1) in the areas
of highest tumor cell density.
EBV status was determined by in situ hybridization for EBER1
and immunohistochemical analysis for the presence of LMP-1 and
EBV nuclear antigen (EBNA)-2. All samples were obtained with
the approval of the Institutional Review Board (IRB) at Okayama
University. The samples were limited to excess human material;
therefore, the IRB exempted the need for written consent from the
patients.
Immunohistochemical analyses
Detection of A20 and EBV was performed on paraffin sections
using the automated Bond Max stainer (Leica Biosystems,
Melbourne, Australia). The primary antibody used and the
dilution rate were A20 (EPR2663 [1:100]; Epitomics, Burlingame,
CA USA). EBV was detected by in situ hybridization for EBER1
(EBER1; Novocastra, Newcastle, UK). In accordance with
previous reports, tumors that comprised of at least 20% of A20-
positive cells were scored as positive [14]. When the internal
positive control cells were not clearly positive for A20, the sample
was classified as ‘‘undetermined’’ or ‘‘equivocal’’. In the ‘‘unde-
termined’’ groups, the tumor cells were negative, and in the
‘‘equivocal’’ groups, the tumor cells were weakly positive.
Further immunohistochemical testing was performed using the
automated Benchmark XT slide stainer (Ventana Medical
Systems, Tucson, AZ, USA). The primary antibodies and the
dilution rate used were as follows: CD20 (L26; [1:200];
Novocastra); CD3 epsilon (PS-1; [1:50]; Novocastra); CD5 (4C7;
[1:100]; Novocastra); CD10 (56C6; [1:50]; Novocastra); CD56
(IB6; [1:25]; Novocastra); Ki-67 (MIB-1; [1:5000]; Novocastra);
LMP-1 (CS1-4; [1:50]; Novocastra); and EBNA-2 (PE2; [1:20];
Dako, Glostrup, Denmark). Membranous, cytoplasmic, and/or
paranuclear dot staining for LMP-1 was evaluated as positive. The
percentage of positive tumor cells was categorized as follows:
positive (.50%); intermediate (,50%); and negative (0%).
Fluorescence in situ hybridization
Dual-color fluorescence in situ hybridization (FISH) of paraffin
sections was performed using the spectrum orange-labeled A20
probe (BAC clones RP11-783B20) and spectrum green-labeled
centromeric probe for chromosome 6 (CEP6) (Vysis/Abbott
Molecular Laboratories, Des Plaines, IL, USA) following the
manufacturers’ instructions [17]. The cell was scored only when
two internal positive control signals (CEP 6) were present, and the
signal ratio of A20 to CEP6 was calculated to evaluate the A20
status. In DLBCL-e, NKTL, and MTX-LPD samples, the
threshold for determining A20 biallelic deletions was the fraction
of signals ranging from 20% to 60%, and that for monoallelic
deletions was from 60% to 80%. For PAL samples, each range was
set from 20% to 40% and from 40% to 80% for biallelic and
monoallelic deletions, respectively. These ranges were different
because there were smaller overlaps of cells in the PAL samples,
and the non-tumor cell contamination was less than that in other
subtypes.
Statistical analysis
Differences in characteristics between the lymphoma subtypes
were determined using the chi-squared test, Fisher’s exact test,
Student’s t-test, or Mann–Whitney U-test, as appropriate. All data
were analyzed with the STATA software (version 10.0; Stata Co.,
College Station, TX, USA). A P value of ,20.05 was considered
statistically significant.
Results
A20 deletion by FISH (Table 1)
Thirteen of 16 PAL, 20 of 33 NKTL, 8 of 9 DLBCL-e, and 11
of 13 MTX-LPD samples provided interpretable results from the
FISH analysis. Of the 13 PAL samples, A20 deletions were
detected in 4 (31%), a biallelic deletion was detected in 1 (8%), and
3 (23%) had monoallelic deletions (Figure 1). In the 20 NKTL
samples, FISH indicated biallelic and monoallelic deletions in 1
(5%) and 2 (10%) samples, respectively (Figure 2). In the 8
DLBCL-e samples, there was no biallelic deletion, and only 1
(13%) sample showed a monoallelic deletion. A20 deletions were
not detected in any of the MTX-LPD samples. Of these 4
lymphoma subtypes, PAL had the highest incidence of A20
deletions. Using a chi-squared test, there were significant
differences in the incidence of A20 deletions between the PAL
and MTX-LPD samples (P=0.044). However, significant differ-
ences were not observed between PAL and NKTL samples
(P=0.28) or between PAL and DLBCL-e samples (P=0.34)
A20 expression by immunohistochemistry
Immunohistochemical staining for A20 was performed on the
samples that provided interpretable results from the FISH analysis,
except for 2 of the NKTL samples for which there was insufficient
sample. The absence of A20 was shown in 2 (15%) PAL samples, 1
(9%) of MTX-LPD samples, and in none of the NKTL or
DLBCL-e samples (Table 2). Two of the 4 PAL samples with A20
deletions, detected by FISH, were immunohistochemically nega-
Table 1. Mono- and Bi-allelic deletions of A20 as determined
by fluorescent in situ hybridization.
Monoallelic Biallelic Total
P value (vs.
PAL)
PAL (n =13) 3 (23%) 1 (8%) 4 (31%) -
NKTL (n=20) 2 (10%) 1 (5%) 3 (15%) 0.28
DLBCL-e
(n=8)
1 (13%) 0 (0%) 1 (13%) 0.34
MTX-LPD
(n=11)
0 (0%) 0 (0%) 0 (0%) 0.044
Abbreviations: PAL, pyothorax-associated lymphoma; NKTL, NK/T cell
lymphoma, nasal type; DLBCL-e, EBV positive diffuse large B-cell lymphoma of
the elderly; MTX-LPD, methotrexate-related lymphoproliferative disorders.
doi:10.1371/journal.pone.0056741.t001
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tive for A20, and the other 2 samples were equivocal. The other
samples, without A20 deletions, were immunohistochemically
positive for A20. None of the NKTL samples were immunohis-
tochemically negative for A20; 2 patients could not be assessed
because of the absence of sufficient sample material, and 1 had
equivocal staining. All DLBCL-e samples were positive for A20,
including the sample demonstrating a monoallelic deletion. For
MTX-LPD, 1 sample was immunohistochemically negative.
EBV latency state (Table 3)
The EBV latency patterns were immunohistochemically exam-
ined using LMP-1 and EBNA-2. Results of LMP-1 determinations
were obtained for all 52 samples and EBNA-2 for 49 samples for
which there were insufficient samples. All of the 12 PAL samples in
which LMP-1 and EBNA-2 were examined showed latency III
(LMP-1+, EBNA-2+), and 1 sample was not examined for EBNA-2
but was positive for LMP-1. Ten (50%) NKTL samples exhibited
intermediate positivity for LMP-1, and all of the NKTL samples
were negative for EBNA-2. All 3 NKTL samples with A20
deletions were negative for LMP-1. In the DLBCL-e samples,
latency I (LMP-12, EBNA-22), II (LMP-1+, EBNA-22), and III
were found in 1, 4, and 3 samples, respectively. One DLBCL-e
sample with monoallelic deletion indicated latency II. Of the
MTX-LPD samples, 5 (46%) expressed latency II, 4 (36%)
expressed latency III, and 2 (18%) expressed latency I. One
sample, immunohistochemically negative for A20, expressed
latency II.
Figure 1. A20 monoallelic deletion in pyothorax-associated
lymphoma. (A) Diffuse proliferation of lymphoid cells, (hematoxylin-
eosin stain, Olympus BX51, magnification6200; inset6400). (B) Positive
signals in the nucleus of almost all tumor cells, (Epstein-Barr virus
encoded RNA1, Olympus BX51, magnification6400). (C) Positive signals
in.50% of the tumor cells, (latent membrane protein-1, Olympus BX51,
magnification 6400). (D) Monoallelic deletion of A20 detected by
fluorescent in situ hybridization. A20 probe (orange) and chromosome 6
centromeric probe (green) (Olympus IX71, colors corrected after
acquisition with Adobe Photoshop).
doi:10.1371/journal.pone.0056741.g001
Figure 2. A20 biallelic deletion in nasal-type NK/T cell
lymphoma. (A) Medium-sized lymphoid cells with slightly irregular
nuclei and mitosis, (hematoxylin-eosin stain, Olympus BX51, magnifi-
cation6200; inset6400). (B) Positive signals in the nucleus of almost all
tumor cells, (EBER1, Olympus BX51, magnification6400). (C) Negative
for latent membrane protein-1 (LMP-1) staining (LMP-1, Olympus BX51,
magnification 6400). (D) Biallelic deletion of A20 detected by
fluorescent in situ hybridization. A20 probe (orange) and chromosome
6 centromeric probe (green). (Olympus IX71, colors corrected after
acquisition with Adobe Photoshop).
doi:10.1371/journal.pone.0056741.g002
Table 2. Samples with A20 deletions and/or the absence of A20 by immunohistochemistry.
Sample No. Diagnosis A20 deletion A20 expression EBER1 (ISH) LMP-1 EBNA-2
1 PAL Homozygous loss 2 + + +
2 PAL LOH 2 + + +
3 PAL LOH +/2 + + +
4 PAL LOH +/2 + + +
5 NKTL Homozygous loss u.d. + 2 2
6 NKTL LOH u.d. + 2 2
7 NKTL LOH +/2 + 2 2
8 DLBCL-e LOH + + + 2
9 MTX-LPD normal 2 + + 2
Abbreviations: PAL, pyothorax-associated lymphoma; NKTL, NK/T cell lymphoma, nasal type; DLBCL-e, EBV positive diffuse large B-cell lymphoma of the elderly; MTX-
LPD, methotrexate-related lymphoproliferative disorders; LOH, loss of heterozygosity; EBER1, Epstein-Barr virus encoded RNA1; LMP-1, latent membrane protein-1;
EBNA-2, EBV nuclear antigen-2; +, positive (50% or more); p+, intermediate expression (less than 50%); 2, negative (0%); +/2, equivocal positive; u.d., undetermined.
doi:10.1371/journal.pone.0056741.t002
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Discussion
In malignant lymphomas, A20 inactivation occurs through
deletion of the A20 locus at 6q23, inactivation mutations, and/or
methylation of the A20 promoter. In addition, some studies have
suggested an association between A20 inactivation and EBV
infection [11,12,14]. Schimitz et al. reported that A20 mutations
or deletions are rarely observed in EBV-positive CHL [11].
However, A20 alteration is seen in certain EBV-related lympho-
mas [11,12,14]. In a previous study, the majority of EBV-positive
AIDS-related lymphoma cases with A20 alterations did not express
LMP-1 [14], and the inactivation of A20 has been proposed as an
alternative mechanism for NF-kB up-regulation in LMP-1-
negative cases [14].
In the current study, 4 of the 13 PAL samples (31%) showed
A20 deletions by FISH, which was higher than that in previous
reports studying other types of non-Hodgkin’s lymphomas
[5,7,8,10,11,14] (Table 4). Compagno et al. showed that A20
inactivation was more common in activated B-cell-like (ABC)-type
DLBCL than in germinal center B-cell-like (GC)-type DLBCL
(24% vs. 2.2%) [9]. According to previous reports [18,19], the
majority of the EBV-positive DLBCL cases have been identified as
having the ABC-phenotype; moreover, PAL cases also express the
ABC-phenotype [20]. To the best of our knowledge, no study has
described the level of NF-kB activation in PAL. However,
constitutive NF-kB activation is a common feature of many
ABC-type DLBCL cells [21]. As PAL results in the expression of
the ABC-phenotype, we suggest that constitutive NF-kB activation
may exist in PAL, and A20 inactivation may contribute to the
pathogenesis of this disease.
As mentioned above, Giulino et al. reported that the majority of
EBV-positive AIDS-related lymphomas, with A20 alterations, do
not express LMP-1 [14]. However, in the present study, A20
deletions were observed to coexist with LMP-1 expression in PAL
and DLBCL-e samples. Most PAL [20,22] and DLBCL-e [19]
tumors are known to be immunohistochemically positive for LMP-
1, and NKTLs are negative, or partially positive, for LMP-1 [23–
25]. The A20 deletion does not correlate with LMP-1 expression,
and it shows a characteristic latency pattern associated with each
lymphoma subtype. Therefore, A20 alterations might not reflect
the previously characterized EBV latency pattern of each
lymphoma subtype, but they may reflect the diagnostic category.
In NKTL, Karube et al. showed that PRDM1 and FOXO3,
rather than A20, contribute to its pathogenesis [26]. In the current
study, 3 of the 20 NKTL samples showed the deletion of A20; this
proportion is not as high as that described in previous reports
[5,7,8,10–14]. Therefore, we do not consider A20 to have a
significant role in the pathogenesis of NKTL.
DLBCL-e also exhibits the ABC-phenotype as well as promi-
nent activation of NF-kB [19]. The current study investigated
whether or not A20 inactivation was found at high frequencies in
DLBCL-e. However, only 1 of the 8 DLBCL-e samples showed
A20 deletions. Although this study suggests that A20 may not
contribute to the pathogenesis of DLBCL-e, this conclusion is
limited by the small sample size. Further research is required to
further elucidate the association between A20 and DLBCL-e.
In cases of MTX-LPD, rheumatoid arthritis —a chronic
inflammatory disease_is often present; however, the frequency of
A20 deletions of MTX-LPD differs from that of PAL. MTX-LPD
and PAL are distinct in that MTX-LPD occasionally regresses
after the withdrawal of MTX, all PAL patients have poor
prognoses. A20 alterations may not be seen in lymphoproliferative
disorders that occasionally show regression. Furthermore, some of
the patients from whom the samples in the present study were
taken also received anti-TNFa, in addition to MTX. Therefore,
the association between the activation of NF-kB and pathogenesis
of B-cell type MTX-LPD may not have been present.
Giulino et al. were the first to report immunohistochemical
findings for A20; they observed that patients with A20 mutations
and/or monoallelic deletions were frequently positive for A20
[14]. Immunohistochemically, 3 samples from the present work
were found to be negative for A20: 2 samples from PAL patients
with biallelic and monoallelic deletions, and 1 sample from a
MTX-LPD patient without an A20 deletion. Therefore, we suggest
that in cases where the samples are negative for A20 and do not
Table 3. Incidence of A20 deletion and latent membrane
protein-1 (LMP-1) status.
LMP-1 Status PAL DLBCL-e NKTL MTX-LPD
LMP-1 + 4/11 (36%) 1/4 (25%) 0/0 0/4 (0%)
LMP-1 +/2 0/2 (0%) 0/3 (0%) 0/10 (0%) 0/5 (0%)
LMP-1 2 0/0 0/1 (0%) 3/10 (30%) 0/2 (0%)
Abbreviations: PAL, pyothorax-associated lymphoma; NKTL, NK/T cell
lymphoma, nasal type; DLBCL-e, EBV positive diffuse large B-cell lymphoma of
the elderly; MTX-LPD, methotrexate-related lymphoproliferative disorders; LMP-
1: +, positive (50% or more); +/2, intermediate expression (less than 50%); 2,
negative (0%).
doi:10.1371/journal.pone.0056741.t003
Table 4. Frequency of literature-reported A20 deletions by fluorescent in situ hybridization.
Authors Subtypes Cases reported Monoallelic Biallelic Total
Novak et al. [5] EMZL n = 11 1 (9%) 1 (9%) 2 (18%)
NMZL n = 9 1 (11%) 1 (11%) 2 (22%)
SMZL n = 12 0 (0%) 0 (0%) 0 (0%)
Chanudet et al. [7] EMZL n = 161 9 (6%) 3 (2%) 12 (8%)
Rossi et al. [13] SMZL n = 101 8 (8%) 1 (1%) 9 (9%)
Bi et al. [8] EMZL n = 105 7 (7%) 2 (2%) 9 (9%)
Dong et al. [10] DLBCL-GI n = 71 0 (0%) 13 (18%) 13 (18%)
Giulino et al. [14] ARL n = 33 1 (3%) 5 (15%) 6 (18%)
Abbreviations: EMZL, extranodal marginal zone lymphoma; NMZL, nodal marginal zone lymphoma; SMZL, splenic marginal zone lymphoma; DLBCL-GI, gastrointestinal
diffuse large B-cell lymphoma; ARL, AIDS-related lymphoma.
doi:10.1371/journal.pone.0056741.t004
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have biallelic deletions, additional alterations of A20, such as a
mutation and/or promoter methylation, might be present.
In this study, A20 deletions and/or dysfunctional expressions
were frequently found in PAL samples (Table 1), suggesting that
A20 inactivation may contribute to its pathogenesis. The
coexistence of an A20 deletion and LMP-1 expression was
detected in PAL and DLBCL-e samples, indicating that A20
deletions and LMP-1 expression are independent characteristics.
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